Pharmacotherapy of suicidal behavior in bipolar disorder.
Patients with Bipolar Disorder (BD) are at particularly high risk for both attempted and completed suicides. The period of highest risk for completed suicide is during the 2 years following discharge from a hospitalization. To date, pharmacological studies of suicidal behavior in BD have been quite limited. While strong evidence has been found regarding the anti-suicidal effects of lithium, evidence for such properties in other commonly prescribed medications for BD, including anticonvulsants, SSRIs and anti-psychotics, has been largely unexplored. Considering the high risk of suicidal acts in patients with BD, further research on the pharmacotherapy of suicidal behavior is crucial.
Oquendo
Maria A
MA
New York State Psychiatric Institute/Columbia University, Department of Neuroscience, New York 10032, USA. moquendo@neuron.cpmc.columbia.edu
Chaudhury
Sadia R
SR
Mann
J John
JJ
D000927:Anticonvulsants / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013405:Suicide / Q000523:psychology*; D000092864:Suicide Prevention
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D017367:Selective Serotonin Reuptake Inhibitors